Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 5.14M | 12.62M | 51.90M | 57.67M | 12.11M | 69.77M |
Gross Profit | 13.69M | 12.62M | 5.62M | 6.01M | -22.30M | 20.07M |
EBITDA | -46.41M | -46.91M | -1.84M | -12.28M | -43.23M | 13.30M |
Net Income | -46.05M | -49.47M | -7.57M | -58.10M | -52.81M | -63.98M |
Balance Sheet | ||||||
Total Assets | 92.94M | 111.06M | 175.19M | 207.86M | 267.50M | 307.42M |
Cash, Cash Equivalents and Short-Term Investments | 60.03M | 80.77M | 92.46M | 101.48M | 119.84M | 151.64M |
Total Debt | 27.03M | 31.00M | 39.89M | 42.25M | 44.25M | 19.09M |
Total Liabilities | 87.79M | 102.22M | 132.29M | 153.71M | 160.06M | 151.45M |
Stockholders Equity | 5.14M | 8.83M | 51.90M | 54.15M | 107.44M | 155.97M |
Cash Flow | ||||||
Free Cash Flow | -41.26M | -7.29M | -34.91M | -20.28M | -59.79M | -63.09M |
Operating Cash Flow | -41.10M | -6.90M | -32.56M | -19.15M | -58.46M | -51.81M |
Investing Cash Flow | 15.24M | 9.20M | 20.63M | 1.88M | -917.00K | -13.37M |
Financing Cash Flow | 8.79M | -6.01M | -1.97M | -1.83M | 26.82M | -1.14M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $215.30M | 109.67 | -51.06% | ― | -44.94% | -274.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $203.65M | ― | -298.41% | ― | 565.52% | 79.44% | |
46 Neutral | $191.97M | ― | -271.32% | ― | -75.77% | -31.24% | |
43 Neutral | $238.90M | ― | -180.71% | ― | ― | 64.43% | |
33 Underperform | $201.33M | ― | ― | ― | ― | -686.12% | |
30 Underperform | $152.76M | ― | -9999.00% | ― | ― | -4.60% |
Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, utilizing innovative approaches such as monoclonal antibodies, NK Cell Engagers, and antibody-drug conjugates. The company is based in Marseille, France, and is publicly traded on Euronext Paris and Nasdaq.
Innate Pharma has launched a Phase 1 clinical study titled ‘A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of IPH4502 in patients with advanced solid tumors expressing Nectin-4, a significant step in cancer treatment research.